StockNASDAQ · US · USDHealthcare · Medical Devices
$UFPT
UFP TECHNOLOGIES INC
UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient medical devices and components for medical device manufacturers. Its products serve applications including minimally invasive surgery, infection prevention, wound care, wearables, orthopedics, interventional and surgical care, therapeutics, diagnostics, and biopharma. Custom products include surgical and endoscopic disposables, protective drapes, wound care products, medical device packaging, and components for implants and catheters. UFP Technologies earns money by developing and manufacturing products to customer specifications, and sells principally through a direct sales force. Its manufacturing processes include molding, cutting, forming, welding, laminating, and assembly. The company has nineteen manufacturing locations that are ISO 13485 certified and thirteen that are FDA registered. It is headquartered in Newburyport, Massachusetts.
UFP Technologies reported Q3 sales growth of 11.6% to $172.4M, driven by MedTech demand. Gross margin improved to 29.4%, and adjusted EPS rose to $2.88. The company highlighted capacity investments and acquisitions, including CI Medical. Challenges include AJR transfer delays and higher SG&A costs. Management expects long-term growth of 6-9% organically and 12-18% with acquisitions, with a softer fourth quarter.
Lyell Immunopharma (LYEL) rose 44% after securing $80M in financing and reporting positive clinical data. LivaNova (LIVN) gained 23% on strong Q3 results and raised guidance. UFP Technologies (UFPT) advanced 22% with 11.6% sales growth and improved profitability. Neuronetics (STIM) rose 21% as Q3 loss narrowed and EBITDA turned positive.
Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged after Democrats regained majorities in Congress, easing drug pricing policy concerns. Analysts expect the biopharmaceutical sector to benefit from reduced regulatory uncertainty. UFP Technologies, up 21.5%, has seen significant volatility and strong performance, including a 51.1% year-to-date gain.
via TradingView
UFPT sentiment & insider activity
Recent UFPT coverage spans earnings, market movers and financial news.
What's driving UFPT
Strong earnings and cash generation suggest upside potential.
AlphAI scores every news story that mentions UFPT with an AI model for sentiment and relevance, and aggregates insider trades from UFP TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
UFP Technologies reported Q3 sales growth of 11.6% to $172.4M, driven by MedTech demand. Gross margin improved to 29.4%, and adjusted EPS rose to $2.88. The company highlighted capacity investments and acquisitions, including CI Medical. Challenges include AJR transfer delays and higher SG&A costs. Management expects long-term growth of 6-9% organically and 12-18% with acquisitions, with a softer fourth quarter.
Lyell Immunopharma (LYEL) rose 44% after securing $80M in financing and reporting positive clinical data. LivaNova (LIVN) gained 23% on strong Q3 results and raised guidance. UFP Technologies (UFPT) advanced 22% with 11.6% sales growth and improved profitability. Neuronetics (STIM) rose 21% as Q3 loss narrowed and EBITDA turned positive.
Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged after Democrats regained majorities in Congress, easing drug pricing policy concerns. Analysts expect the biopharmaceutical sector to benefit from reduced regulatory uncertainty. UFP Technologies, up 21.5%, has seen significant volatility and strong performance, including a 51.1% year-to-date gain.
UFP Technologies (UFPT) reported Q3 2026 revenue of $172.4M, up 11.6% YoY and 3.2% above estimates. Adjusted EPS of $2.88 beat estimates by 7.3%. Operating margin held steady at 16%. The company cited operational improvements and growth in new programs. Analysts expect 5.6% revenue growth over the next 12 months.
UFP TECHNOLOGIES INC (UFPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. UFP Technologies Announces Strong Q3 Results Newburyport, Mass., November 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly
Azenta reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B revenue, up 8.7% YoY, exceeding expectations. UFP Technologies reported $174M revenue, up 15.1% YoY, with the largest analyst estimate beat. West Pharmaceutical Services reported $872.3M revenue, up 13.8% YoY, topping expectations. All stocks have seen post-earnings gains.
Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.
Argus raised its price target for UFP Technologies (UFPT) to $334, citing strong recent performance and growth prospects. The stock has gained 34.60% year-to-date and 54.03% over one year. Analysts estimate a fair value of $355, but the stock trades at a P/E of 32.2x, higher than its industry average. The company's expansion and medical sector focus drive optimism, though risks include customer concentration and integration challenges.
UFP Technologies, Inc. (UFPT) completed the acquisition of CI Medical Inc. on September 7, 2026. The company's stock has seen a 5-day change of 288.79 USD, a 1st Jan change of +0.79%, and a year-to-date change of +30.07%.
UFP Technologies (UFPT) reported record Q2 profits of $20.9M, up 21.4% YoY, with net sales of $174.0M, up 15.1%. Gross margin rose to 29.3%, but SG&A expenses increased 21.8%, raising concerns. CEO noted near-term margin pressure due to Dominican Republic operations. Hedge fund interest declined, and short interest is high at 19.26% of float.